Bioequivalence of granisetron HCl orally disintegrating tablet in Chinese healthy volunteers
Zhiwen Jiang
Abstract
Zhiwen Jiang
Abstract
Objective:To study the pharmacokinetics of granisetron HCl orally disintegrating tablet and compare its relative bioavailability with domestic granisetron tablet.Methods:Twenty healthy volunteers were administered a single oral dose of domestic granisetron HCl orally disintegrating tablet or tablet(reference)in a randomized crossover study,and their plasma drug concentration was determined by HPLC-fluoremetry.Results:The plasma concentration-time curve was fitted to one-compartment model.The pharmacokinetic parameters obtained were:Cmax=(7.2±3.4)μg/L,t1/2 =(4.2±1.8)h,tmax =(1.3±0.3)h,AUC0~24 h=(37.3±25.6)μg·h·L.No significant difference was found between the test and the reference groups.The relative bioavailability obtained was(97.9±19.2)%.Conclusions:The two preparations are bioequivalent.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective:To study the pharmacokinetics of granisetron HCl orally disintegrating tablet and compare its relative bioavailability with domestic granisetron tablet.Methods:Twenty healthy volunteers were administered a single oral dose of domestic granisetron HCl orally disintegrating tablet or tablet(reference)in a randomized crossover study,and their plasma drug concentration was determined by HPLC-fluoremetry.Results:The plasma concentration-time curve was fitted to one-compartment model.The pharmacokinetic parameters obtained were:Cmax=(7.2±3.4)μg/L,t1/2 =(4.2±1.8)h,tmax =(1.3±0.3)h,AUC0~24 h=(37.3±25.6)μg·h·L.No significant difference was found between the test and the reference groups.The relative bioavailability obtained was(97.9±19.2)%.Conclusions:The two preparations are bioequivalent.
Key concepts: Bioequivalence, Granisetron, Medicine, Bioavailability, Pharmacokinetics, Cmax, Pharmacology, Crossover study